Salix Pharmaceuticals Enterprise Value:
3.835B for May 17, 2013Salix Pharmaceuticals Historical Enterprise Value Data
Pro Data ExportThere is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| May 17, 2013 | 3.835B |
| May 16, 2013 | 3.829B |
| May 15, 2013 | 3.864B |
| May 14, 2013 | 3.835B |
| May 13, 2013 | 3.776B |
| May 10, 2013 | 3.704B |
| May 9, 2013 | 3.522B |
| May 8, 2013 | 3.542B |
| May 7, 2013 | 3.533B |
| May 6, 2013 | 3.515B |
| May 3, 2013 | 3.511B |
| May 2, 2013 | 3.432B |
| May 1, 2013 | 3.407B |
| April 30, 2013 | 3.407B |
| April 29, 2013 | 3.400B |
| April 26, 2013 | 3.360B |
| April 25, 2013 | 3.303B |
| April 24, 2013 | 3.279B |
| April 23, 2013 | 3.249B |
| April 22, 2013 | 3.242B |
| April 19, 2013 | 3.173B |
| April 18, 2013 | 3.128B |
| April 17, 2013 | 3.188B |
| April 16, 2013 | 3.214B |
| April 15, 2013 | 3.209B |
| April 12, 2013 | 3.231B |
| April 11, 2013 | 3.258B |
| April 10, 2013 | 3.247B |
| April 9, 2013 | 3.226B |
| April 8, 2013 | 3.234B |
| April 5, 2013 | 3.288B |
| April 4, 2013 | 3.293B |
| April 3, 2013 | 3.298B |
| April 2, 2013 | 3.363B |
| April 1, 2013 | 3.303B |
| March 28, 2013 | 3.339B |
| March 27, 2013 | 3.282B |
| March 26, 2013 | 3.326B |
| March 25, 2013 | 3.315B |
| March 22, 2013 | 3.310B |
| March 21, 2013 | 3.351B |
| March 20, 2013 | 3.301B |
| March 19, 2013 | 3.229B |
| March 18, 2013 | 3.230B |
| March 15, 2013 | 3.237B |
| March 14, 2013 | 3.233B |
| March 13, 2013 | 3.199B |
| March 12, 2013 | 3.205B |
| March 11, 2013 | 3.192B |
| March 8, 2013 | 3.232B |
About Enterprise Value
Click "Learn More" below to see how YCharts calculates Enterprise Value.
Enterprise Value (EV) is a valuation metric alternative to traditional market capitalization that reflects the market value of an entire business. Like market cap, EV is a measure of what the market believes a company is worth. Enterprise value captures the cost of an entire business, including debt and equity. It is a sum of claims of all preferred shareholders, debt holders, security holders, common equity holders, and minority shareholders - unlike market cap, which only captures the total value of common equity securities.
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Learn More
SLXP Enterprise Value Benchmarks
| Companies | |
|---|---|
| Catalyst Pharmaceutical Partners | 18.76M |
| Valeant Pharmaceuticals International | 34.11B |
| Auxilium Pharmaceuticals | 272.27M |
SLXP Enterprise Value Rankings
| Overall |
84th percentile 1156 of 7590 |
| Sector |
84th percentile 98 of 651 in Healthcare |
| Industry |
80th percentile 13 of 65 in Drug Manufacturers - Specialty & Generic |
SLXP Enterprise Value Range, Past 5 Years
| Minimum | 194.61M | Sep 17 2008 |
| Maximum | 3.864B | May 15 2013 |
| Average | 1.801B |
SLXP News
Business Wire May 17
